A method of treating acne in a human in need thereof comprising administering orally or intravenously to said human an antibiotic tetracycline compound in a sub-antibacterial amount that reduces lesion count, said amount being 10–80% of the antibacterial effective amount, wherein the tetracycline compound is administered long term, without administering a bisphosphonate compound. view more

A method according to claim 1, wherein said acne is acne rosacea.

A method according to claim 1, wherein the antibiotic tetracycline compound is in an amount that is 40–70% of the antibacterial effective amount.

A method according to claim 24, wherein the lesions are pustules and papules.

A method according to claim 1, wherein the sub-antibacterial amount is an amount that results in no reduction of skin microflora during a six-month treatment.

A method according to claim 26, wherein the sub-antibacterial amount is an amount that results in no reduction of skin microflora during a six-month treatment.

A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a tetracycline compound, or a pharmaceutically acceptable salt thereof, in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount that results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound. view more

A method according to claim 1, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.

A method according to claim 12, wherein said doxycycline is doxycycline monohydrate.

A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.

A method according to claim 14, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.

A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a hydrate of doxycycline in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the hydrate of doxycycline is administered in an amount that results in no reduction of skin microflora during a six-month treatment, said method not comprising administering a bisphosphonate compound. view more

A method according to claim 20, wherein said hydrate of doxycycline is doxycycline monohydrate.

A method according to claim 20, wherein said hydrate of doxycycline is administered in an amount of 40 milligrams.

A method according to claim 20, wherein said hydrate of doxycycline is administered by sustained release.

A method according to claim 23, wherein said hydrate of doxycycline is administered once a day.

A method of inhibiting expression of inducible nitric oxide synthase in a mammal system, comprising administering to said mammal system an amount of a tetracycline compound sufficient to inhibit inducible nitric oxide synthase expression in said mammal system. view more

The method according to claim 1, wherein the tetracycline compound has substantially no anti-microbial activity in said mammal system.

The method according to claim 1, wherein the tetracycline compound is 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), 6-.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline (CMT-8), 4-dedimethylaminotetracycline (CMT-1), doxycycline, or minocycline. view more

The method according to claim 1, wherein said mammal system is a mammal having a condition characterized by increased nitric oxide production.

The method according to claim 1, wherein said mammal system is a mammal having a condition characterized by an abnormally high level of activity of inducible nitric oxide synthase.

A method for inhibiting nitric oxide production in a mammal system, comprising providing to the mammalian system an amount of a tetracycline compound sufficient to cause a decrease in the amount of nitric oxide produced endogenously by the mammalian-system. view more

The method according to claim 1, wherein the tetracycline compound has substantially no anti-microbial activity in the mammal system.

The method according to claim 1, wherein the tetracycline compound is 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), 6-.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline (CMT-8), 4-dedimethylaminotetracycline (CMT- 1), doxycycline, or minocycline. view more

A method for treating a mammal having a medical condition characterized by excess endogenous production of nitric oxide, comprising administering to the mammal an amount of a tetracycline compound sufficient to inhibit endogenous nitric oxide production in the mammal. view more

The method according to claim 11, wherein the medical condition is a chronic inflammatory condition.

The method according to claim 11, wherein the tetracycline compound has substantially no anti-microbial activity in the mammal.